Key facts
- It has raised $1.9M across 1 recorded rounds; the latest was Seed Round ($554K) in Apr 2024.
- Notable investors include US National Science Foundation, Invest Detroit Ventures, Lateral Capital Management, Michigan Economic Development, Alligator Holdings — 12 tracked in total.
- StabiLux Biosciences has filed 1 Form D with the SEC, most recently May 2024 ($554K sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for StabiLux Biosciences
Funding rounds
1 roundsAbout StabiLux Biosciences
Developer of high-brightness fluorophores designed to improve the reagents that run through flow cytometers. The company's fluorophores are compatible with current flow cytometers and increase the brightness of fluorophores across the visible range with minimal or no noise distortion, enabling users to detect targeted or cancer cells feasibly.
- Sector
- Healthcare
- HQ
- Ann Arbor, MI, United States
- Founded
- 2014
- Employees
- 9
- Website
- stabilux-biosciences.com/
- Ownership
- Privately Held (backing)
StabiLux Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in StabiLux Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on StabiLux Biosciences in its N-PORT filings yet. We sweep new filings monthly.